Abstract. This study was undertaken to identify novel approaches to pharmacological treatment of asthma. Here we hypothesize that the platelet-activating factor receptor antagonist ginkgolide B (GB) in combination with the antioxidant carotenoid astaxanthin (ASX) suppresses T cell activation comparably to two commonly-used antihistamines: cetirizine dihydrochloride (CTZ) and azelastine (AZE). Peripheral blood mononuclear cells from asthmatics, cultured 24 h with either 50 mg / ml phytohemaglutinin (PHA) or PHA plus selected dosages of each drug are analyzed by flow cytometry for CD25+ or HLA-DR+ on CD3+ (T cells). Results are reported as stimulation indices (SI) of %CD3+CD25+ cells or %CD3+HLA-DR+ cells in cultures treated with PHA alone versus these subpopulations in cultures treated with both PHA and drugs. Combinations of ASX and GB exhibited optimal suppression at 10 -7 M GB + 10 -8 M ASX for CD3+CD25+ (SI = 0.79 ± 0.04, P = 0.001) and 10 -7 M GB + 10 -7 M ASX for CD3+HLA-DR+ (SI = 0.82 ± 0.05, P = 0.004). In conclusion, suppression of T cell activation below fully stimulated values by GB, ASX, and their combinations was comparable and for some combinations better than that mediated by CTZ and AZE. These results suggest that ASX and GB may have application as novel antiasthmatic formulations.
Introduction
Previously we have characterized immunological features of diseases in Kuwaiti populations following the Gulf War of 1991 (1 -7) with the objective of identifying novel therapeutic targets and indicators of treatment efficacy. Concurrently we have evaluated various categories of pharmacological agents in order to determine maximally effective formulations with the fewest side effects. Our preliminary studies suggested that extracts of Ginkgo biloba offer substantial promise to mediate minimally toxic suppression of the fundamental processes underlying immune activation and inflammation when used in combination with other drugs (8) . Subsequent studies of asthma in our laboratory revealed that ginkgolide B (GB), a terpene lactone component of Ginkgo biloba with antioxidant and plateletactivating factor (PAF)-inhibitory properties, affected in vitro activation of T lymphocytes from asthma patients by a pathway distinct from the immunosuppressive drug cyclosporin A (9) . We further observed that suppression of asthmatic T cell activation mediated by cyclosporin A is substantially augmented by co-administration of GB (10) .
Regimens of treatment for asthma may include either immunosuppressives (11) or corticosteroids (12) ; however, the adverse side effects associated with these drugs (13) make antihistamines a favored approach by primary care physicians when it is possible to avoid steroid use. Two antihistamines, cetirizine dihydrochloride (CTZ) (marketed as Zyrtec) and azelastine (AZE) (marketed as Astelin) have application in management of asthma (14 -18) . We have therefore chosen them as a nonsteroidal standard for comparative study in this investigation. There are, however, side effects associated with use of both agents: Asthma patients treated with AZE over extended time periods report taste disorders, asthenia, and weight gain (19) ; with one report of the drug inducing a seizure in an epileptic patient being treated for asthma (20) . CTZ is known to have hepatotoxic properties (21, 22) and despite its classification as a non-sedating antihistamine, drowsiness and fatigue are also associated with its use in some patients (23) ; and it has additionally been reported to induce urticaria (24) . Hence therapy based on naturally-occuring products with few side-effects is a desireable alternative to these and similar agents. Our formulations based on GB and the powerful, naturally-occurring antioxidant, astaxanthin (ASX), potentially offer such an alternative. Dose ranges for each antihistamine were selected on the basis of ongoing evaluations of the effect of each drug independently on the same variables measured in the present study (25) .
Here we hypothesize that formulations based on the combined activity of GB and ASX will prove equal or superior to CTZ, AZE, and similar agents in treating asthma, but with substantially lower adverse effects with long-term use. In the present study, we begin to test this hypothesis by evaluating the capacity of CTZ or AZE to suppress lectin-mediated activation of T cells from the blood of asthmatic patients in vitro. This is compared with the effectiveness of GB, ASX, and their combinations in affecting the same parameters. The experimental approach we use in these evaluations involves comparison of the degree to which T lymphocytes from asthmatic patients undergo immune activation in vitro when stimulated with phytohemaglutinin (PHA), versus stimulation with PHA plus selected formulations of ASX, GB, or each of the two antihistamines chosen for this study. In each case, the baseline condition is defined by expression of cell surface activation antigens in the fully-stimulated culture, with drug effects measured using this as a reference value.
This study was conducted with the understanding that inhibition of T cell activation is not a major antiasthmatic mechanism of antihistamines such as ASX and CTZ. However, given the powerful effects of drugs that act through T cell inhibition to remediate symptoms of asthma such as corticosteroids, FK506 and cyclosporine A, it is reasonable to hypothesize that drugs which affect T cell activity may also impact downstream events in asthma pathogenesis. Ultimately, results of this investigation are expected to provide the basis for development of novel therapies based on interaction of these GB and ASX.
Materials and Methods

Patients
Subjects for this study included 14 Kuwaiti patients diagnosed with atopic asthma, 7 male and 5 female, ranging in age from 21 to 40 years (mean 28 ± 1.8 years), with disease duration ranging from 2 to 12 years. A cohort of 5 non-asthmatic participants, 3 males and 2 females ranging in age from 22 -35 years (mean 27 ± 1.5 years), was also included as case controls for this investigation. All asthma patients had been referred to the outpatient clinic of the Medicine Department, Mubarak Hospital, Kuwait. All patients fulfilled the criteria of the International Consensus Report on Diagnosis and Management of Asthma (26) . Atopy was defined on the basis of one or more positive skin prick tests to a range of 20 allergens. None of the patients had received systemic therapy for at least 6 weeks prior to blood collection. Mean serum IgE levels for asthmatic participants in this study was 335 (170 -480) IU / ml and 110 (90 -120) IU / ml for the non-asthmatic control group. Informed consent was obtained from every patient.
Cell cultures
Blood samples from at least 5 patients and 5 healthy control subjects were used as a basis for determination of drug effects on peripheral blood mononuclear cell (PBMC) activation for each independent assay performed. Venous blood for each subject was collected in polyethylene tubes containing EDTA during a one-hour morning time interval. PBMC were separated by Ficollpaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Cells were washed and suspended in RPMI 1640 medium (Gibco BRL, Gaithersburg, MD, USA) at a density of 1´10 6 cells / ml. PBMC were stimulated with 50 m g / ml PHA (Sigma M AZE (Wallace Pharmaceuticals, Somerset, NJ, USA), followed by evaluation of cultures for the same biological endpoints as ASX/ GB-treated cells. Each reagent was added at the outset of a 24-h culture period, followed by harvesting of the cellular fraction for immunophenotyping studies.
Flow cytometric analysis
Cells harvested from cultures by centrifugation were incubated for 30 min at 4°C with 10 ml each of flourescein-isothiocyanate (FITC)-CD3 and phycoerythrin (RD1)-CD25 or HLA-DR conjugated monoclonal antibodies (mAb) (Dakopatts, A / S, Glostrup, Denmark), followed by fixation with paraformaldehyde. Two-color flow cytometry was conducted using a Coulter Altra automated flow cytometer (Coulter Scientific, Hialeah, FL, USA). Isotypic controls for the mAb used to detect antigens of interest were established for each cell preparation. Positive analysis regions for cells expressing specific surface markers were set against controls and specific binding of fluorophore-conjugated mAb was analyzed by cytofluorography according to standard methods recommended by the manufacturer. Lymphocyte subpopulations were identified by position on forward and side scatter plots and live-gated. Expression of each antigen was reported as percentage cells positive for a particular T cell subpopulation defined by expression of CD3 (T lymphocyte marker) plus CD25 or HLA-DR, plus or minus standard error.
Measurement of drug effects
The capacity of formulations evaluated in this study to suppress immune activation was measured as a stimulation index (SI), defined as the ratio of CD3+CD25+ cells or CD3+HLA-DR+ cells in each test condition to CD3+CD25+ cells or CD3+HLA-DR+ cells in cultures treated with PHA alone. Fully stimulated cultures (cells treated with 50 m g / ml PHA) are assigned SI values of 1.00 and compared with values for CD3+CD25+ and CD3+HLA-DR+ in cultures treated with selected formulations of ASX, GB, AZE, and CTZ.
Statistical analyses
Statistical analysis was performed using an independent t-test. All statistical analyses were performed using the SPSS for Windows statistical package (Norusis / SPSS, Inc., Chicago, IL, USA). A value of P<0.05 was considered statistically significant. (Table 1) Culture of PBMC for 24 h with 50 mg/ ml of the immunostimulatory lectin PHA resulted in significant activation of T lymphocytes in asthmatic subjects, measured as increased percentage of CD3+CD25+ cells or CD3+HLA-DR+ cells versus unstimulated cultures. In unstimulated cultures, CD3+CD25+ cells represented 3.26 ± 1.25% of the CD3 compartment and increased to 35.06 ± 3.7% by treatment with PHA (P = 0.000). CD3+HLA-DR+ cells represented 12.90 ± 1.59% of T cells at baseline, which was expanded to 29.58 ± 4.8% following PHA stimulation (P = 0.008). PHA-mediated expansion of activated T cells from healthy individuals was of the same order of magnitude as cells taken from blood of asthmatic subjects. The percentage of CD3+CD25+ cells in control cultures increased from 1.66 ± 0.47 to 29.02 ± 4.7 (P = 0.007), while CD3+HLA-DR+ cells increased from 5.9 ± 0.77 to 37.7 ± 2.1 (P = 0.000). Effects of CTZ and AZE on T lymphocyte activation (Table 2) The ability of CTZ and AZE to inhibit PHA-induced expansion of activated human T lymphocyte subpopulations in vitro was evaluated over a 3-log dose range from 10 -8 -10 -6 M for each drug. In cultures from asthma patients, significant suppression of PHA-induced CD3+CD25+ T cell activation was mediated by CTZ at 10 -8 M (SI = 0.71 ± 0.12, P = 0.024) and 10 -7 M (SI = 0.68 ± 0.09, P = 0.002) and by AZE also at 10 -8 M (SI = 0.81 ± 0.08, P = 0.033) and 10 -7 M (SI = 0.85 ± 0.07, P = 0.035). Both drugs also exhibited ability to significantly suppress PHA-induced expansion of CD3+HLA-DR T cells. CTZ inhibited expansion of this subpopulation at 10 -8 M (SI = 0.47 ± 0.13, P = 0.009), 10 -7 M (SI = 0.58 ± 0.11, P = 0.010), and 10 -6 M (SI = 0.70 ± 0.04, P = 0.001). Significant inhibition by AZE was seen at 10 -8 M (SI = 0.55 ± 0.09, P = 0.001), 10 -7 M (SI = 0.56 ± 0.10, P = 0.006), and 10 -6 M (SI = 0.61 ± 0.13, P = 0.018). The effect of each antihistamine on PHA-activated cells from the non-asthmatic, control cohort was considerably less. Neither drug significantly suppressed expansion of the CD3+CD25+ subpopulation. However increases in CD3+HLADR+ were suppressed by AZE at 10 -6 M (SI = 0.77 ± 0.05, P = 0.020).
Results
T lymphocyte activation
Effects of ASX and GB on T lymphocyte activation (Table 3) PHA-induced expansion of CD3+CD25+ subpopulations from asthma patients were suppressed significantly by ASX at a concentration of 10 -4 M (SI = 0.49 ± 0.07, P = 0.000) and 10 -7 M (SI = 0.86 ± 0.06, P = 0.017). Significant effects by ASX on the size of CD3+HLA-DR+ populations was only seen in cultures treated with 10 -8 M of the compound (SI = 0.74 ± 0.11, P = 0.028). In PBMC cultures from healthy control subjects, significant suppression of PHA-induced CD3+CD25+ subpopulations occurred at an ASX concentration of 10 -4 M (SI = 0.64 ± 0.08, P = 0.004) and at 10 -6 M ASX for CD3+HLA-DR+ cells (SI = 0.88 ± 0.05, P = 0.043). For cultures of cells from asthma patients, GB significantly reduced PHA-induced increases in CD3+CD25+ populations at 10 -6 M (SI = 0.80 ± 0.09, P = 0.021) and 10 -8 M (SI = 0.87 ± 0.04, P = 0.011), with a significant suppression of CD3+HLA-DR+ cells at a dosage of 10 -6 M (SI = 0.66 ± 0.06, P = 0.001). In cultures from blood of healthy control subjects, GB failed to significantly suppress induction of CD3+CD25+, but suppressed CD3+HLD-DR+ cells at 10 -6 M (SI = 0.87 ± 0.06, P = 0.050) and 10 -7 M (SI = 0.85 ± 0.07, P = 0.050). Combined effects of ASX plus GB on T lymphocyte activation (Table 4) Combinations of ASX and GB also significantly suppressed immune activation by PHA. In PHA-stimulated cultures of PBMC from asthma patients, maximal suppression of CD3+CD25+ induction by PHA was observed when cultures were treated with 10 -7 M GB + 10 -8 M ASX (SI = 0.79 ± 0.04, P = 0.001); and maximum suppression of CD3+HLA-DR+ cells was seen at 10 -7 M GB + 10 -6 M ASX (SI = 0.61 ± 0.05, P = 0.002). For cultures of cells from healthy control subjects, maximal suppression of CD3+CD25+ cells by combinations of GB and ASX occurred at 10 -7 M GB + 10 -8 M ASX (SI = 0.66 ± 0.07, P = 0.009). Combined treatment with GB and ASX failed to result in significant suppression of CD3+HLA-DR+ at any of the concentrations evaluated. Finally, the effect of 10 -8 M ASX + 10 -7 M GB on PHA-induced expansion of CD3+CD25+ was significantly greater than 10 -8 M ASX alone (P = 0.019) in asthmatic subjects. In cells from control subjects, combining 10 -7 M GB with 10 -8 M ASX resulted in lower CD3+CD25+ levels than 10 -8 M ASX alone (P = 0.031), or 10 -7 M GB alone (P = 0.035), demonstrating that GB and ASX interact at those concentrations to achieve improved levels of suppression.
Discussion
Therapy for relief of asthmatic symptoms includes use of "second-generation antihistamines" such as CTZ and AZE, which have been developed to minimize the sedation and anticholinergic adverse effects that occur with older H1-receptor antagonists. In addition to their primary mechanisms of H1-receptor blockade and inhibition of histamine release, these agents may act upstream of these events and affect T lymphocyte activation, ultimately influencing pathogenic processes dependent on T cells. In this study, we examined the Cells from 3 -14 asthma patients (plain text) and 3 -5 healthy control subjects (bold text) were cultured 24 h with 50 m g/ml PHA, or PHA plus selected dosages of ASX or GB. PBMC evaluated by 2-color flow cytometry were gated for CD3+ and analyzed for CD3+CD25+ or CD3+HLA-DR+ as a percentage of the CD3+ population. Results are reported as stimulation indices (SI) calculated as the ratio of %CD3+CD25+ cells or %CD3+HLA-DR+ cells in fully-stimulated baseline cultures to %CD3+CD25+ or %CD3+HLA-DR+, respectively, in cells treated with PHA plus ASX or GB.
capacity of CTZ and AZE to suppress activation of T lymphocytes from asthmatic subjects in vitro and compared these results with the ability of ASX and GB to affect the same parameters. The model of T cell activation used in this study utilizes PHA-mediated induction of the activation antigens CD25 (the IL-2 receptor) and the human leukocyte antigen-DR (HLA-DR), both of which are known to be upregulated in asthmatics during the pathogenesis of asthma (27, 28) and are also increased by culture with PHA in vitro.
As shown in Table 1 , treatment of cells with PHA increased CD3+CD25+ subpopulations by a factor of approximately 11, whereas PHA approximately doubled the size of the CD3+HLA-DR+ population. It was observed that both CTZ and AZE at a culture concentrations in the range of 10 -8 -10 -7 M significantly suppressed T cell activation, measured by the ability of the drugs to inhibit PHA-dependent increases of both CD3+CD25+ and CD3+HLA-DR+ cells (Table 2) . Although culture of cells with ASX at 10 -4 M in addition to PHA caused a substantial inhibition of increases in the CD3+CD25+ population, similar effects were not noted in the case of CD3+HLA-DR+ cells (Table 3) . Interestingly, when GB and ASX were combined at concentrations of 10 -7 M and 10 -8 M, respectively, and added to PHA-stimulated cultures, significant suppression of both CD3+CD25+ and CD3+HLA-DR+ populations were noted (Table 4) . Additionally GB at a concentration of 10 -7 M augmented the capacity of 10 -8 M ASX to suppress T cell activation ( Table 4) , suggesting that at those concentrations a cooperative effect exists.
Finally, it was noted that generally, each agent evaluated in this study acting alone was less able to suppress PHA-activated cells from healthy, control individuals, than from asthmatics. This is particularly true in the case of the antihistamines. However when ASX and GB are co-administered, their combined effect appears capable of suppressing PHA-mediated activation of cells from both asthmatic and healthy individuals, albeit with different patterns of dosage-effectiveness. Since antihistamine interaction with lymphocytes is not considered to be a major contributor to their therapeutic effects, the degree to which such interactions occur has not been extensively explored. Lymphocytes, in particular T cells, often act as master switches for extensive cascades of immunological processes. As an example, during the pathogenesis of atopic asthma, Th2 cells in the lung express cytokines (principally IL-5) that interact with eosinophils to cause a massive release of inflammatory mediators, resulting in events which include mast-cell sensitization, further eosinophil and lymphocyte recruitment, and mucus secretion (29) . Hence, agents that have relatively minor effects on lymphocyte activation may ultimately cause major changes in multiple processes coordinated by T cells. Therefore, the suppression of T cell activation by antihistamines observed in this study may be accounted for by the fact that cellular signalling pathways that promote tissue damage in asthma exert positive feedback and increase T cell activation (30, 31) . By this analysis, drugs that inhibit release of inflammatory metabolites or their biological activity are also expected to exhibit immunosuppressive properties. Indeed, the H1-receptor antagonist terfenadine is observed to inhibit proliferation and expression of IL-4 and IL-5 production by anti-CD3 / -CD28 and PMA-activated human T cells in vitro (32) . Since both of these Th2 cytokines are implicated as major factors in asthma pathogenesis, it is probable that therapeutic effects of this drug are mediated at least in part by suppression of T cell activity. The ability of GB and ASX to combine in suppression of T cell activation may be accounted for based on the properties of each compound. PAF-inhibitory ginkgolides such as GB affect the same cellular signaling pathways that are used by calcineurin inhibitors to suppress T cell-dependent immune activation. Engagement of PAF with its complementary receptor causes the release of calcium from cellular stores, activation of calcineurin, and ultimately, expression of genes contributing to immune activation in T cells (33) . Inhibition of this process at the level of calcineurin suppresses T cell activity but is associated with serious side effects. The process may also be inhibited by blocking PAF activity. Ginkgolides offer a desirable approach to this due to their low toxicity (34) . Hence, their antiinflammatory properties offer high potential for therapeutic use.
Significant contribution to tissue damage in asthma is also made by reactive oxygen species (ROS); however, no therapies specifically target this aspect of its pathogenesis (35) . A logical approach to this problem is to administer an antioxidant as a therapeutic agent, in addition to drugs aimed at other features of the disease. The carotenoid ASX is an attractive candidate for this task since its antioxidant properties would be expected to reduce ROS-mediated tissue damage. Its antioxidant properties also may account for the effects reported in this study. ROS are substantially upregulated by T lymphocytes during PHA-mediated activation; moreover, blocking this enhancement with antioxidants such as glutathione radically alters the activation process, causing either increased or decreased T cell activity dependent on the ratio of ROS-inducing agents to antioxidants (36 -38) . This phenomenon may help explain the observation that suppression of PHA-induced T cell activation did not exhibit dose-dependency with any of the drugs (Tables 2 and 3 ). If T cells are activated under several different conditions of ROS concentration, then patterns of activation and suppression would be observed at ratios of drugs that influenced ROS production. This could occur at very low drug concentrations, or higher dosages.
This analysis however is speculative and would require further investigation to confirm. A complete mechanistic picture accounting for the results of this study remains largely to be defined. However, our findings are consistent with our hypothesis that the properties of ASX and GB may act in concert to suppress activation of T cells from asthma patients. This may ultimately allow development of improved therapies based on these compounds.
